Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell Transplantation
NCT01267812 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 23
Last updated 2023-07-27
Summary
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving bortezomib together with rituximab may kill more cancer cells.
PURPOSE: This phase II trial is studying how well giving bortezomib and rituximab together works in treating patients with mantle cell lymphoma who have previously undergone stem cell transplantation
Conditions
- Contiguous Stage II Mantle Cell Lymphoma
- Noncontiguous Stage II Mantle Cell Lymphoma
- Recurrent Mantle Cell Lymphoma
- Stage I Mantle Cell Lymphoma
- Stage III Mantle Cell Lymphoma
- Stage IV Mantle Cell Lymphoma
Interventions
- DRUG
-
Given SC or IV
- BIOLOGICAL
-
Given IV
- OTHER
-
laboratory biomarker analysis
Correlative studies
- OTHER
-
immunohistochemistry staining method
Correlative studies
- GENETIC
-
RNA analysis
Correlative studies
- GENETIC
-
gene expression analysis
Correlative studies
- GENETIC
-
DNA analysis
Correlative studies
- OTHER
-
pharmacological study
Correlative studies
- OTHER
-
pharmacogenomic studies
Correlative studies
- OTHER
-
Questionnaire Administration
Sponsors & Collaborators
-
National Cancer Institute (NCI)
collaborator NIH -
City of Hope Medical Center
lead OTHER
Principal Investigators
-
Matthew Mei · City of Hope Medical Center
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 19 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2011-10-03
- Primary Completion
- 2020-11-02
- Completion
- 2020-11-02
Countries
- United States
Study Locations
More Related Trials
-
An Efficacy and Tolerability Study of Bortezomib in Combination With Rituximab Standard Therapy in Participants With Relapsed or Refractory Follicular Lymphoma
NCT01902862 ·Status: TERMINATED ·Phase: PHASE2
-
S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma
NCT01412879 ·Status: COMPLETED ·Phase: PHASE2
-
Ixazomib & Rituximab After Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma in Remission
NCT02632396 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Bortezomib, Combination Chemotherapy, and Rituximab as First-Line Therapy in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's Lymphoma
NCT00428142 ·Status: COMPLETED ·Phase: PHASE2
-
Sequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma
NCT02633137 ·Status: COMPLETED ·Phase: PHASE2
-
A Prospective, Single-Center Study Evaluating the Efficacy and Safety of Glofitamab Combined With Orelabrutinib and Bortezomib in Patients With High-Risk Mantle Cell Lymphoma
NCT06656221 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma
NCT00980395 ·Status: COMPLETED ·Phase: PHASE2
-
Carfilzomib Consolidation Therapy After Autologous Stem Cell Transplantation (ASCT) for Mantle Cell Lymphoma (MCL), T-cell Lymphoma (TCL), and Diffuse Large B-Cell Lymphoma (DLBCL)
NCT01926665 ·Status: COMPLETED ·Phase: PHASE1
-
Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission
NCT03267433 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory Low-Grade, Follicular, or Mantle Cell Non-Hodgkin's Lymphoma
NCT00334438 ·Status: COMPLETED ·Phase: PHASE1
-
Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma
NCT01695941 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma
NCT01216683 ·Status: COMPLETED ·Phase: PHASE2
-
Rituximab and Interleukin-12 in Treating Patients With B-Cell Non-Hodgkin's Lymphoma
NCT00026182 ·Status: COMPLETED ·Phase: PHASE2
-
Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma
NCT01045928 ·Status: TERMINATED ·Phase: PHASE1
-
Combination Chemotherapy With or Without Rituximab in Treating Patients With Mantle Cell Lymphoma
NCT00053092 ·Status: COMPLETED ·Phase: PHASE2
-
Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma
NCT06675123 ·Status: RECRUITING ·Phase: PHASE1
-
Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma
NCT00126191 ·Status: TERMINATED ·Phase: PHASE2
-
Treatment of Mantle Cell Lymphoma at Diagnosis for Patients Under 65 Years
NCT00285389 ·Status: COMPLETED ·Phase: PHASE2
-
A Combination Study of CAR-T Therapy in r/r B-NHL
NCT05871684 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell Lymphoma
NCT05564052 ·Status: COMPLETED ·Phase: PHASE2
-
Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma
NCT01318317 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Trial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Untreated Low Grade Lymphoma
NCT01029730 ·Status: COMPLETED ·Phase: PHASE2
-
A Randomised Evaluation of Molecular Guided Therapy for Diffuse Large B-cell Lymphoma With Bortezomib
NCT01324596 ·Status: COMPLETED ·Phase: PHASE3
-
Ofatumumab With or Without Bendamustine for Patients With Mantle Cell Lymphoma Ineligible for Autologous Stem Cell Transplant
NCT01437709 ·Status: COMPLETED ·Phase: PHASE2
-
Immunochemotherapy With Rituximab-Bendamustine-Cytarabine (R-BAC) for Patients With Mantle Cell Lymphoma
NCT00992134 ·Status: COMPLETED ·Phase: PHASE2